

Tuberculosis

Why in News

Centenary celebration is being observed for the **Bacille Calmette-Guérin (BCG)** vaccine, which is presently the **sole vaccine** available for the prevention of **Tuberculosis (TB)**.

Key Points

About:

- TB is caused by a bacterium called Mycobacterium tuberculosis, belonging to the Mycobacteriaceae family consisting of about 200 members.
 - Some of Mycobacteria cause diseases like TB and Leprosy in humans and others infect a wide range of animals.
- In humans, TB **most commonly affects the lungs** (pulmonary TB), but it can also affect other organs (extra-pulmonary TB).
- TB is a very ancient disease and has been documented to have existed in Egypt as early as 3000 BC.
- TB is a treatable and curable disease.

Transmission:

• TB is **spread from person to person through the air.** When people with lung TB cough, sneeze or spit, they propel the TB germs into the air.

Symptoms:

 Common symptoms of active lung TB are cough with sputum and blood at times, chest pains, weakness, weight loss, fever and night sweats.

Global Impact of TB:

- In 2019, 87% of new TB cases occurred in the 30 high TB burden countries.
- Eight countries accounted for two thirds of the new TB cases:
 - India, Indonesia, China, Philippines, Pakistan, Nigeria, Bangladesh and South Africa.
 - **India reported 1.8 million TB cases** between January and December 2020 as compared to 2.4 million the year before.
- In 2019, MDR-TB remained a public health crisis and a health security threat.
 - MultiDrug Resistant Tuberculosis (MDR-TB) is a strain of TB that cannot be treated with the two most powerful first-line treatment anti-TB drugs. Extensively Drug Resistant Tuberculosis (XDR-TB) is a form of TB caused by bacteria that are resistant to several of the most effective anti-TB drugs.

BCG Vaccine:

BCG was developed by two Frenchmen, Albert Calmette and Camille Guerin, by modifying
a strain of Mycobacterium bovis (that causes TB in cattle). It was first used in
humans in 1921.

- In India, BCG was first introduced in a limited scale in 1948 and became a part of the National TB Control Programme in 1962.
- In addition to its primary use as a vaccine against TB, it protects against respiratory and bacterial infections of the newborns, and other mycobacterial diseases like Leprosy and Buruli's ulcer.
- It is also used as **an immunotherapy agent** in cancer of the urinary bladder and malignant melanoma.
- One intriguing fact about BCG is that it works well in some geographic locations and not so well in others. Generally, the farther a country is from the equator, the higher is the efficiency.
 - It has a high efficacy in the UK, Norway, Sweden and Denmark; and little or no efficacy in countries on or near the equator like India, Kenya and Malawi, where the burden of TB is higher.

Related Initiatives:

Global Efforts:

- The <u>WHO (World Health Organisation)</u> has launched a joint initiative "Find. Treat. All. #EndTB" with the <u>Global Fund</u> and <u>Stop TB Partnership</u>.
- WHO also releases the **Global Tuberculosis Report.**

India's Efforts:

- National Strategic Plan (NSP) for Tuberculosis Elimination (2017-2025), The Nikshay Ecosystem (National TB information system), Nikshay Poshan Yojana (NPY- financial support), TB Harega Desh Jeetega Campaign.
- Currently, two vaccines VPM (Vaccine Projekt Management) 1002 and MIP (Mycobacterium Indicus Pranii) have been developed and identified for TB, and are under Phase-3 clinical trial.

Source: TH

PDF Reference URL: https://www.drishtiias.com/printpdf/tuberculosis-3